News NICE close to clearing Cancer Drugs Fund backlog Only five drugs left to assess from old scheme.
News Novo Nordisk may drop US insulin price as Sanofi suffers Biosimilar Lantus is causing rivals to cut prices to compete
News NICE recommends Celgene pancreatic cancer drug Abraxane finally gets NHS funding following price cut.
Views & Analysis Transparently opaque: drug list prices versus net prices The pros and cons of keeping drug pricing agreements confidential.
News Roche's Tecentriq hits trouble with NICE in bladder cancer Cancer Drugs Fund could cover costs in first line use.
Views & Analysis Demonstrating value – the future for market access With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
